These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 34997451)

  • 1. Impacts of genotypic variants on survival following reoperation for recurrent glioblastoma.
    Dono A; Zhu P; Holmes E; Takayasu T; Zhu JJ; Blanco AI; Hsu S; Bhattacharjee MB; Ballester LY; Kim DH; Esquenazi Y; Tandon N
    J Neurooncol; 2022 Jan; 156(2):353-363. PubMed ID: 34997451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic alterations predictive of response to radiosurgery in recurrent IDH-WT glioblastoma.
    Dono A; Amsbaugh M; Martir M; Smilie RH; Riascos RF; Zhu JJ; Hsu S; Kim DH; Tandon N; Ballester LY; Blanco AI; Esquenazi Y
    J Neurooncol; 2021 Mar; 152(1):153-162. PubMed ID: 33492602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Craniotomy for recurrent glioblastoma: Is it justified? A comparative cohort study with outcomes over 10 years.
    Mukherjee S; Wood J; Liaquat I; Stapleton SR; Martin AJ
    Clin Neurol Neurosurg; 2020 Jan; 188():105568. PubMed ID: 31739155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PTEN mutations predict benefit from tumor treating fields (TTFields) therapy in patients with recurrent glioblastoma.
    Dono A; Mitra S; Shah M; Takayasu T; Zhu JJ; Tandon N; Patel CB; Esquenazi Y; Ballester LY
    J Neurooncol; 2021 May; 153(1):153-160. PubMed ID: 33881725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Initial surgical resection and long time to occurrence from initial diagnosis are independent prognostic factors in resected recurrent IDH wild-type glioblastoma.
    Seyve A; Lozano-Sanchez F; Thomas A; Mathon B; Tran S; Mokhtari K; Giry M; Marie Y; Capelle L; Peyre M; Carpentier A; Feuvret L; Sanson M; Hoang-Xuan K; Honnorat J; Delattre JY; Ducray F; Idbaih A
    Clin Neurol Neurosurg; 2020 Sep; 196():106006. PubMed ID: 32554237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimizing Recurrent Glioblastoma Salvage Treatment: A Multicenter Study Integrating Genetic Biomarkers From the Korean Radiation Oncology Group (21-02).
    Kim D; Lee JH; Kim N; Lim DH; Song JH; Suh CO; Wee CW; Kim IA
    Neurosurgery; 2024 Sep; 95(3):584-595. PubMed ID: 38511935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surgical outcome and molecular pattern characterization of recurrent glioblastoma multiforme: A single-center retrospective series.
    Montemurro N; Fanelli GN; Scatena C; Ortenzi V; Pasqualetti F; Mazzanti CM; Morganti R; Paiar F; Naccarato AG; Perrini P
    Clin Neurol Neurosurg; 2021 Aug; 207():106735. PubMed ID: 34119900
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Li J; Zhang Q; Ge P; Zeng C; Lin F; Wang W; Zhao J
    Dis Markers; 2020; 2020():8888085. PubMed ID: 33299501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes.
    Labussière M; Boisselier B; Mokhtari K; Di Stefano AL; Rahimian A; Rossetto M; Ciccarino P; Saulnier O; Paterra R; Marie Y; Finocchiaro G; Sanson M
    Neurology; 2014 Sep; 83(13):1200-6. PubMed ID: 25150284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reoperation for Recurrent Glioblastoma and Its Association With Survival Benefit.
    Tully PA; Gogos AJ; Love C; Liew D; Drummond KJ; Morokoff AP
    Neurosurgery; 2016 Nov; 79(5):678-689. PubMed ID: 27409404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival and functional status after resection of recurrent glioblastoma multiforme.
    Barker FG; Chang SM; Gutin PH; Malec MK; McDermott MW; Prados MD; Wilson CB
    Neurosurgery; 1998 Apr; 42(4):709-20; discussion 720-3. PubMed ID: 9574634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Negative prognostic impact of epidermal growth factor receptor copy number gain in young adults with isocitrate dehydrogenase wild-type glioblastoma.
    Hoffman DI; Abdullah KG; McCoskey M; Binder ZA; O'Rourke DM; Desai AS; Nasrallah MP; Bigdeli A; Morrissette JJD; Brem S; Bagley SJ
    J Neurooncol; 2019 Nov; 145(2):321-328. PubMed ID: 31542863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor recurrence or treatment-related changes following chemoradiation in patients with glioblastoma: does pathology predict outcomes?
    Patrizz A; Dono A; Zhu P; Tandon N; Ballester LY; Esquenazi Y
    J Neurooncol; 2021 Mar; 152(1):163-172. PubMed ID: 33481149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beyond sequence variation: assessment of copy number variation in adult glioblastoma through targeted tumor somatic profiling.
    McNulty SN; Cottrell CE; Vigh-Conrad KA; Carter JH; Heusel JW; Ansstas G; Dahiya S
    Hum Pathol; 2019 Apr; 86():170-181. PubMed ID: 30594748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of
    Dono A; Ramesh AV; Wang E; Shah M; Tandon N; Ballester LY; Esquenazi Y
    Neurooncol Adv; 2021; 3(1):vdab050. PubMed ID: 34131647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comprehensive analysis of factors related to carmustine/bevacizumab response in recurrent glioblastoma.
    Cardona AF; Rojas L; Wills B; Ruiz-Patiño A; Abril L; Hakim F; Jiménez E; Useche N; Bermúdez S; Mejía JA; Ramón JF; Carranza H; Vargas C; Otero J; Archila P; Rodríguez J; Rodríguez J; Behaine J; González D; Jacobo J; Cifuentes H; Feo O; Penagos P; Pineda D; Ricaurte L; Pino LE; Vargas C; Marquez JC; Mantilla MI; Ortiz LD; Balaña C; Rosell R; Zatarain-Barrón ZL; Arrieta O
    Clin Transl Oncol; 2019 Oct; 21(10):1364-1373. PubMed ID: 30798512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and NGS predictors of response to regorafenib in recurrent glioblastoma.
    Chiesa S; Mangraviti A; Martini M; Cenci T; Mazzarella C; Gaudino S; Bracci S; Martino A; Della Pepa GM; Offi M; Gessi M; Russo R; Martucci M; Beghella Bartoli F; Larocca LM; Lauretti L; Olivi A; Pallini R; Balducci M; D'Alessandris QG
    Sci Rep; 2022 Sep; 12(1):16265. PubMed ID: 36171338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Presence of Histopathological Treatment Effects at Resection of Recurrent Glioblastoma: Incidence and Effect on Outcome.
    Dalle Ore CL; Chandra A; Rick J; Lau D; Shahin M; Nguyen AT; McDermott M; Berger MS; Aghi MK
    Neurosurgery; 2019 Dec; 85(6):793-800. PubMed ID: 30445646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Residual tumor volume and patient survival following reoperation for recurrent glioblastoma.
    Yong RL; Wu T; Mihatov N; Shen MJ; Brown MA; Zaghloul KA; Park GE; Park JK
    J Neurosurg; 2014 Oct; 121(4):802-9. PubMed ID: 25061868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EGFR amplification is a real independent prognostic impact factor between young adults and adults over 45yo with wild-type glioblastoma?
    Armocida D; Pesce A; Frati A; Santoro A; Salvati M
    J Neurooncol; 2020 Jan; 146(2):275-284. PubMed ID: 31889239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.